Annotated Medicine and Device Lists

Gliclazide

Solid oral dosage form 30 mg Solid oral dosage form 60 mg Solid oral dosage form 80 mg Tablet (controlled release) 30 mg Tablet (controlled release) 60 mg Tablet (controlled release) 80 mg

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	18.5.2 Oral hypoglycaemic agents	Others observations: Controlled-release tablets. Therapeutic alternatives: 4th level ATC chemical subgroup (A10BB Sulfonylureas). Glibenclamide not suitable above 60 years.

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	18.5.2 Oral hypoglycaemic agents	Others observations: Controlled-release tablets. Therapeutic alternatives: 4th level ATC chemical subgroup (A10BB Sulfonylureas). Glibenclamide not suitable above 60 years.

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	18.5.2 Oral hypoglycaemic agents	Others observations: Controlled-release tablets. Therapeutic alternatives: 4th level ATC chemical subgroup (A10BB Sulfonylureas). Glibenclamide not suitable above 60 years.

This medicine is present in:

List	Section	Observation
PAHO Strategic Fund Medicine List	8.2. Insulins and other antidiabetic agents	Others observations: Glibenclamide not suitable above 60 years.

This medicine is present in:

List	Section	Observation
PAHO Strategic Fund Medicine List	8.2. Insulins and other antidiabetic agents	Others observations: Glibenclamide not suitable above 60 years.

This medicine is present in:

List	Section	Observation
PAHO Strategic Fund Medicine List	8.2. Insulins and other antidiabetic agents	Others observations: Glibenclamide not suitable above 60 years.

Information Resources: Gliclazide

No information available